ViaCyte, Inc.

Vertex remains bullish on prospects for developing curative, endogenous insulin-sparing cell therapies for type 1 diabetes, despite disappointing results unveiled on 28 March that led the Boston-based

Confidence in a potential curative treatment for Type 1 diabetes is growing after Vertex showed three people given its cell therapy, VX-880, lived without insulin injections for a year. New data fro

Vertex is continuing to exceed expectations with the worldwide growth of its cystic fibrosis therapies, but it is now gearing up for a busy 2023, during which a handful of mid- and late-stage assets

Vertex Pharmaceuticals Incorporated will acquire the privately held stem cell therapy developer ViaCyte, Inc. for $320m in cash to expand its pipeline and development flexibility in type 1 diabetes